Venture Capital News: R1 Therapeutics Inks $80.5M Series A Expansion
2026-09-30
Tweet
REDWOOD CITY, CA, R1 Therapeutics, a clinical-stage biopharmaceutical company, announced an expansion of its Series A financing to $80.5 million.
R1 Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, announced an expansion of its Series A financing to $80.5 million, with new investment from Samsara BioCapital.
Samsara BioCapital joins an investor syndicate that includes Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital (previously Symbiosis Capital Management) and U.S. Renal Care, following the oversubscribed $77.5 million round announced in March 2026.
Samsara BioCapital joins an investor syndicate that includes Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital (previously Symbiosis Capital Management) and U.S. Renal Care, following the oversubscribed $77.5 million round announced in March 2026.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
